ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1259

Characteristics of Sacroiliac Joint in Patient with Skin Psoriasis, Without Rheumatological Manifestations: A Controlled Study Using CT Scan
Abstract Number: 0860

Characteristics of Transitioning JIA Patients: Who Is Arriving on the Adult Rheumatologists’ Doorsteps?
Abstract Number: 0438

Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Abstract Number: 1018

Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study
Abstract Number: 1034

Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Abstract Number: 1485

Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus
Abstract Number: 1738

Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases
Abstract Number: 0579

Characterization of Terminal Uridyl Transferase Function in Response to Tumor Necrosis Factor-α in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1305

Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
Abstract Number: 2190

Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis
Abstract Number: 1234

Characterizing Imaging Phenotypes in PsA: The Effect of Age and Sex
Abstract Number: 0092

Characterizing Levels of Specialist Care Received by Patients with Systemic Lupus Erythematosus: Clinical Characteristics, Emergency Care, Hospitalization, and Costs Among Commercially-insured Adults in the United States
Abstract Number: 1848

Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Abstract Number: 1925

Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series
Abstract Number: 0029

Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].